Australia Drug Approvals | Drugs approved by TGA
Jan 20, 2022 Novavax, a protein COVID19 vaccine, is approved provisionally in Australia. The Therapeutic Goods Administration (TGA) in...
Namasthe
Find the healthcare and drug approval news of India, China, Japan, Australia and other Asian countries
Australia Healthcare News | Drug reimbursement
Braftovi was included in the PBS in Australia for bowel cancer The Australian government has announced that it has included Braftovi...
COVID-19 India Updates | Covaxin approved for children | Vaccines for teenagers
India started vaccination of adolescents; Bharat Biotech says Covaxin demonstrated robust efficacy and safety in people of age 2-18 years...
China released the 2022 NDRL list, Chinese pharma benefited from the list
China has released the 2021 Drug catalog, which included 2,860 drugs, out of which 1,486 drugs are Western drugs. Reuters reported a...
Despite facing criticism on handling the COVID19 situation, Tedros to continue as WHO chief
The U.N. agency World Health Organisation (WHO) had made a statement on the next WHO chief. WHO announced that the member states proposed...
WHO granted EUL to Covaxin; acclaims easy storage requirement
WHO has announced that it has granted emergency use listing for Covaxin developed by Bharat Biotech. This adds another vaccine to the...
Levima received orphan designation from MHLW |Japan drug approvals | Japan Healthcare System
Mar 12. 2021 Takeda’s New Drug Application was submitted for MHLW in Japan for Hereditary Angioedema Attacks Takeda announced that it...
Expected best selling pharmaceutical products (drugs) in 2021
SALES FORECAST OF TOP PHARMACEUTICALS IN 2021 Nature Reviews Drug Discovery and Evaluate Pharma published the 2021 sales forecast of...
Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio
Novartis entered a strategic collaboration with BeiGene to license tislelizumab; to market in major markets outside China, including...
Bayer submitted vericiguat for market authorization in China
Bayer has announced that it has submitted an application requesting the approval of vericiguat in China for the treatment of chronic...
Bayer’s Xofigo received approval for prostate cancer in China
Bayer has announced that the Chinese National Medical Products Administration (NMPA) approved Xofigo (radium-223 dichloride) for treating...
Merck’s Keytruda received one more indication and dosage form approval in Japan
Merck has announced that it has received the approval of its anti-PD-1 therapy, Keytruda (pembrolizumab) for radically unresectable,...
AZ received one more approval in Japan, received approval of Imfinzi for SCLC
The Japanese Ministry of Health, Labor, and Welfare approved AstraZeneca’s Imfinzi (durvalumab) for treating patients with...
JAPAN HEALTHCARE SYSTEM
INTRODUCTION Japan has a population of 126 million, nearly twice the size of the UK population. Japan is the third-largest economy. The...
China’s National Medicinal Products Administration approved Gilead’s Truvada
Gilead has announced that China’s National Medicinal Products Administration has approved Truvada (emtricitabine 200mg/tenofovir...
Eisai's Dayvigo was approved in Japan and Hong Kong for insomnia
Approval of Dayvigo in Japan On July 6th, 2020, Eisai announced that it had launched Dayvigo (lemborexant) in Japan for insomnia. The...
Merck’s Keytruda approved in China for esophageal squamous cell carcinoma
Merck has announced that it has received approval from the Chinese National Medical Products Administration (NMPA) in China for Keytruda...
GSK and Clover Biopharmaceuticals begins COVID-19 vaccine Phase 1 clinical trial
GSK has announced that Clover Biopharmaceuticals initiated the Phase 1 trial of COVID-19 vaccine SCB-2019. The vaccine was given in...
May witnessed the approval of Pfizer’s Talzenna, Nyprax’s Tukysa, Drug Houses’ Ajovy in Singapore
In Singapore, the Health Sciences Authority has approved three new products in May. Ajovy approved for migraine in adults Tuksya approved...
Gilead announced the positive Phase 3 trial of remdesivir in COVID-19 patients
Gilead has announced top-line Phase 3 trial results of remdesivir in patients with COVID-19. The drug is indicated in moderate COVID-19...
Astellas announced approval of Xospata in China
Astellas has announced the approval of Xospata (gilteritinib) for relapsed (disease that has returned) or refractory (resistant to...